Openbookopenbook
Equity
argenx SE(ARGNF)
USD --+0.00%
Reward67High
Risk27Low
📊75%Data
Strong 31% profit margin · Revenue growing 73% YoY
ARGNF
+0.0 · +0.00%
USD · OTCGREY
argenx SE | Healthcare
Growth Machine
Market Cap:47.47Bn
ℹ️
Reward Rating
67
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
27
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ARGNF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is argenx SE?

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.

ARGNF · Verdict

Solid reward · low risk

ARGNF stands out on growth and cash flow, but watch the valuation signal.

Based on 88% data coverage

ARGNF · Verdict

What’s working & what to watch

Strengths 4

  • Growth90/100

    Revenue +116.2% CAGR

  • Cash flow82/100

    14% free-cash-flow margin

  • Profitability78/100

    31% net margin · 20% ROE

  • Volatility75/100

    Above average

Watchouts 1

  • Valuation18/100

    P/E 27.2× · PEG 1.16

Model-based scoring. For information only — not financial advice.

What is argenx SE?

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is listed on the OTCGREY in USA, operating in the Healthcare sector, with a market capitalisation of 47.47B, and a P/E ratio of 37.0x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (67)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap47.47B
P/E Ratio37.0424
Dividend YieldN/A
52 Week High872.27
52 Week Low532.4
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding62M
No. of Employees1,863
IndustryBiotechnology
ExchangeOTCGREY
Beta-0.087
CurrencyUSD
Websiteargenx.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.